JAMA lambastes Vioxx articles

Share this article:
The Journal of the American Medical Association called into question published clinical data and authorship surrounding Merck's Vioxx (rofecoxib) in a scathing editorial. 

The hubbub stems from two articles printed in the April 16 issue, which offer a microscopic look at documents obtained during Vioxx lawsuits and litigation.

JAMA asserts that “clinical trial articles and review articles related to rofecoxib frequently were written by unacknowledged authors who were employees of for-profit information industries…” Merck refuted the charges in a statement claiming that the JAMA reports related to Vioxx “are false, misleading or lack context.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...